Improving cancer immunotherapy by targeting IL-1

Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhilan Xiao, Shubhra Singh, Manisha Singh
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	inflammation il-1 cancer immunotherapy Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fbc895f8725448949ed32765c4489559
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fbc895f8725448949ed32765c4489559
record_format	dspace
spelling	oai:doaj.org-article:fbc895f8725448949ed32765c44895592021-11-26T11:19:49ZImproving cancer immunotherapy by targeting IL-12162-402X10.1080/2162402X.2021.2008111https://doaj.org/article/fbc895f8725448949ed32765c44895592021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/2162402X.2021.2008111https://doaj.org/toc/2162-402XInterleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.Zhilan XiaoShubhra SinghManisha SinghTaylor & Francis Grouparticleinflammationil-1cancerimmunotherapyImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoImmunology, Vol 10, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inflammation il-1 cancer immunotherapy Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	inflammation il-1 cancer immunotherapy Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zhilan Xiao Shubhra Singh Manisha Singh Improving cancer immunotherapy by targeting IL-1
description	Interleukin-1 (IL-1) is an inflammatory cytokine associated with tumor invasiveness and metastasis. We recently found that baseline IL-1 in melanomas promoted resistance to immunotherapy by creating an immunosuppressive tumor microenvironment and that IL-1 produced in response to CD40 agonist also induced resistance to therapy. Here, we discuss how naturally occurring and immunotherapy-induced IL-1 in tumors causes immune suppression and resistance to immunotherapy, and we discuss targeting the IL-1 pathway to enhance the efficacy of immunotherapy.
format	article
author	Zhilan Xiao Shubhra Singh Manisha Singh
author_facet	Zhilan Xiao Shubhra Singh Manisha Singh
author_sort	Zhilan Xiao
title	Improving cancer immunotherapy by targeting IL-1
title_short	Improving cancer immunotherapy by targeting IL-1
title_full	Improving cancer immunotherapy by targeting IL-1
title_fullStr	Improving cancer immunotherapy by targeting IL-1
title_full_unstemmed	Improving cancer immunotherapy by targeting IL-1
title_sort	improving cancer immunotherapy by targeting il-1
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/fbc895f8725448949ed32765c4489559
work_keys_str_mv	AT zhilanxiao improvingcancerimmunotherapybytargetingil1 AT shubhrasingh improvingcancerimmunotherapybytargetingil1 AT manishasingh improvingcancerimmunotherapybytargetingil1
_version_	1718409511001128960

Improving cancer immunotherapy by targeting IL-1

Ejemplares similares